Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9219 |
High Similarity |
NPD3027 |
Phase 3 |
0.8846 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8769 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8722 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8722 |
High Similarity |
NPD1613 |
Approved |
0.8346 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.832 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8308 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8306 |
Intermediate Similarity |
NPD228 |
Approved |
0.8284 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8209 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.8182 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8182 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.8162 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8121 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8106 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.8045 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8 |
Intermediate Similarity |
NPD3021 |
Approved |
0.8 |
Intermediate Similarity |
NPD3022 |
Approved |
0.8 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7956 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7933 |
Intermediate Similarity |
NPD1934 |
Approved |
0.791 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7868 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7792 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7786 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7786 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7778 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.777 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7769 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7763 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7717 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7708 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7697 |
Intermediate Similarity |
NPD37 |
Approved |
0.7662 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.766 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.766 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7639 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7635 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7619 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7581 |
Intermediate Similarity |
NPD846 |
Approved |
0.7581 |
Intermediate Similarity |
NPD940 |
Approved |
0.7568 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7548 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7548 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7548 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7548 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7547 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7547 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7547 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7533 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7533 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7532 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD3705 |
Approved |
0.75 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7468 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7466 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7453 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7419 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7413 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7413 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7407 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7405 |
Intermediate Similarity |
NPD5494 |
Approved |
0.74 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7397 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7397 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7397 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7394 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7388 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7386 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7375 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7372 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7365 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7364 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7362 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7346 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7344 |
Intermediate Similarity |
NPD968 |
Approved |
0.7343 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7338 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7338 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7338 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7333 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7319 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7319 |
Intermediate Similarity |
NPD2230 |
Approved |
0.7319 |
Intermediate Similarity |
NPD2232 |
Approved |
0.731 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7308 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7301 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7279 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7278 |
Intermediate Similarity |
NPD4055 |
Discovery |
0.7273 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7273 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7273 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7273 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7273 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7273 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7267 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7256 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7248 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7246 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7239 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7237 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.723 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7229 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7226 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7226 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7214 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7211 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7211 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7211 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.72 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7192 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7181 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7177 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7177 |
Intermediate Similarity |
NPD2859 |
Approved |
0.7172 |
Intermediate Similarity |
NPD943 |
Approved |
0.7171 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD7261 |
Clinical (unspecified phase) |
0.7154 |
Intermediate Similarity |
NPD290 |
Approved |
0.7143 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7143 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7143 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7124 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7123 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7123 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7113 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7108 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7101 |
Intermediate Similarity |
NPD2667 |
Approved |
0.7101 |
Intermediate Similarity |
NPD2668 |
Approved |
0.7097 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7097 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7097 |
Intermediate Similarity |
NPD2934 |
Approved |
0.7092 |
Intermediate Similarity |
NPD2922 |
Phase 1 |
0.7086 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7086 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7086 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7078 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7071 |
Intermediate Similarity |
NPD1608 |
Approved |
0.707 |
Intermediate Similarity |
NPD5089 |
Approved |
0.707 |
Intermediate Similarity |
NPD5090 |
Approved |
0.7066 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7063 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7059 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7059 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7051 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.705 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7045 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7044 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7042 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7039 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7039 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7027 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7027 |
Intermediate Similarity |
NPD6895 |
Approved |
0.7027 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7027 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD6896 |
Approved |
0.7024 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.702 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.702 |
Intermediate Similarity |
NPD4237 |
Approved |
0.702 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7014 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7013 |
Intermediate Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7007 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7006 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6788 |
Approved |
0.7 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD4624 |
Approved |
0.6986 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6985 |
Remote Similarity |
NPD709 |
Approved |
0.6984 |
Remote Similarity |
NPD288 |
Approved |
0.6981 |
Remote Similarity |
NPD2977 |
Approved |
0.6981 |
Remote Similarity |
NPD2978 |
Approved |
0.6978 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6978 |
Remote Similarity |
NPD5846 |
Approved |
0.6974 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD7466 |
Approved |
0.6974 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6972 |
Remote Similarity |
NPD1283 |
Approved |
0.6964 |
Remote Similarity |
NPD7240 |
Approved |
0.6963
|
Remote Similarity |
NPD1398 |
Phase 1 |